
    
      PRIMARY OBJECTIVES:

      I. Clinical response rate at 6 months? percent of patients with complete response and partial
      response at 6 months.

      SECONDARY OBJECTIVES:

      I. Histologic response rate at 6 months. II. Change in clinical impression based on
      photographs of the lesion. III. Clinical response rate at 9 months and 12 months. IV.
      Toxicity.

      EXPLORATORY OBJECTIVES:

      I. PD-L1 expression in leukoplakia lesions and biomarker analysis.

      OUTLINE:

      Participants receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Courses
      repeat every 3 weeks for 6 months in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, participants are followed up at 30 days and every 3
      months for 2 years.
    
  